Literature DB >> 28842286

Incidence and risk factors of acute kidney injury in the Japanese trauma population: A prospective cohort study.

Jun Fujinaga1, Akira Kuriyama2, Noriaki Shimada3.   

Abstract

INTRODUCTION: Previous studies have reported the prevalence and risk factors of acute kidney injury (AKI) in relatively young trauma patients. The aims of this study were to identify the prevalence and risk factors of AKI among older Japanese trauma patients.
METHODS: We conducted a prospective observational study in the 8-bed intensive care unit (ICU) of a Japanese tertiary-care hospital. Participants comprised trauma patients aged 18 years or older admitted to the ICU. Our primary outcome was the incidence of AKI within 10days of admission, according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.
RESULTS: Among 333 patients, 66 (19.8%) developed AKI (Stage 1, n=54; Stages 2, n=5; and Stage 3, n=7). Multivariate logistic regression analysis revealed that the incidence of AKI was associated with increased age (odds ratio (OR), 1.38; 95% confidence interval (CI), 1.15-1.65), male sex (OR, 2.06; 95%CI, 1.04-4.07), greater amount of red blood cell transfusions (OR, 1.61; 95%CI, 1.04-1.17), and presence of underlying chronic kidney disease (CKD) (OR, 3.97; 95%CI, 1.78-8.83). Length of stay in the ICU was significantly longer in patients with AKI (6days) than in those without (3days; p<0.001). Patients ≥65 years old were more likely to develop AKI (26.2% vs 11.6%; p<0.001). No significant differences in ICU stay (median, 4 vs 4days; p=0.70), hospital stay (median, 24 vs 21days; p=0.45), or 28-day mortality (2.1% vs 1.4%; p=0.19) were evident between age groups.
CONCLUSIONS: Approximately 20% of trauma patients developed AKI, and the elderly were more likely to develop AKI. Older age, male, greater units of red blood cell transfusions, and underlying CKD were associated with incidence of AKI.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Aged; Chronic kidney disease; Contrast; Observational study; Risk factors

Mesh:

Year:  2017        PMID: 28842286     DOI: 10.1016/j.injury.2017.08.022

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  6 in total

1.  Health-related quality of life in trauma patients at 12 months after injury: a prospective cohort study.

Authors:  Nobuichiro Tamura; Akira Kuriyama; Toshie Kaihara
Journal:  Eur J Trauma Emerg Surg       Date:  2018-08-22       Impact factor: 3.693

2.  Acute kidney injury in trauma patients admitted to the ICU: a systematic review and meta-analysis.

Authors:  Signe Søvik; Marie Susanna Isachsen; Kine Marie Nordhuus; Christine Kooy Tveiten; Torsten Eken; Kjetil Sunde; Kjetil Gundro Brurberg; Sigrid Beitland
Journal:  Intensive Care Med       Date:  2019-02-06       Impact factor: 17.440

3.  Global Perspectives in Acute Kidney Injury: Japan.

Authors:  Hiroyuki Yamada; Motoko Yanagita
Journal:  Kidney360       Date:  2022-03-29

4.  Single Graft Utilization From Donors With Severe Acute Kidney Injury After Circulatory Death.

Authors:  Yusuke Tomita; Kazuhiro Iwadoh; Yuichi Ogawa; Katsuyuki Miki; Kotaro Kai; Akihito Sannomiya; Toru Murakami; Ichiro Koyama; Kumiko Kitajima; Ichiro Nakajima; Shohei Fuchinoue
Journal:  Transplant Direct       Date:  2018-03-19

5.  Incidence and epidemiology of acute kidney injury in a pediatric Malawian trauma cohort: a prospective observational study.

Authors:  Erica C Bjornstad; William Muronya; Zachary H Smith; Keisha Gibson; Amy K Mottl; Anthony Charles; Stephen W Marshall; Yvonne M Golightly; Charles K Munthali; Emily W Gower
Journal:  BMC Nephrol       Date:  2020-03-14       Impact factor: 2.388

6.  Predictors of mortality of trauma patients admitted to the ICU: a retrospective observational study☆.

Authors:  Matthaios Papadimitriou-Olivgeris; Eleftheria Panteli; Kyriaki Koutsileou; Maria Boulovana; Anastasia Zotou; Markos Marangos; Fotini Fligou
Journal:  Braz J Anesthesiol       Date:  2020-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.